Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 27, 2021 Expiration: July 26, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca
Lipika Goyal, MD
R. Kate Kelley, MD
Amit G. Singal, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Identify patients with biliary tract cancers most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC or BTC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Lipika Goyal, MD, MPhil, has disclosed that she has received consulting fees from Alentis, AstraZeneca, Exelixis, and Sirtex, consulting fees and research support paid to her institution from Genentech, H3Biomedicine, Incyte, QED Therapeutics, Servier, and Taiho, and research support paid to her institution from Adaptimmune, Bayer, Bristol-Myers Squibb, Eisai, Leap Therapeutics, Loxo Oncology, MacroGenics, Merck, Novartis, Nucana, and Relay Therapeutics.
R. Kate Kelley, MD

Associate Professor
Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

R. Kate Kelley, MD, has disclosed that she has received funds for research support paid to her institution from Adaptimmune, Agios, AstraZeneca, Bayer, Bristol-Myers Squibb, EMD Serono, Exelixis, Lilly, Merck, Novartis, Partner Therapeutics, QED, Relay Therapeutics, and Taiho and consulting fees from Exact Sciences, Genentech/Roche, Gilead Sciences, and Ipsen.
Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Roche/Genentech, and Wako.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists, hepatologists, radiation oncologists, surgical oncologists, and other healthcare providers who treat patients with HCC and BTC.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with HCC and BTC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 27, 2021, through July 26, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers
  • CME

Loading...
In this interactive recording of a live CCO webinar, experts discuss current best practices and emerging strategies for using immune checkpoint inhibitors to treat patients with hepatobiliary cancers.
Lipika Goyal, MD
R. Kate Kelley, MD
Amit G. Singal, MD, MS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 27, 2021 Expiration: July 26, 2022

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Enter the characteristics of your patients with pancreatic cancer into this online tool from Clinical Care Options (CCO) to receive expert treatment recommendations

Andrew H. Ko, MD
Program Director
Elena Gabriela Chiorean, MD Dan Laheru, MD person default Paul E. Oberstein, MD Michael J. Pishvaian, MD, PhD
Released: September 13, 2021

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

On-demand video from Clinical Care Options (CCO) with expert perspectives on using biomarkers to inform treatments for GI cancers

David H. Ilson, MD, PhD John L. Marshall, MD Eric Van Cutsem, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 16, 2021 Expired: August 15, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue